| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/25/2003 | US20030236224 Increasing the vascular half life of starch by oxidizing and reducing the starch and administering the oxidized and reduced starch into the circulation of a mammal |
| 12/25/2003 | US20030236223 For slowing tumor growth, decreasing cell proliferation, decreasing neovascularization and blocking metastatic spread |
| 12/25/2003 | US20030236222 For the prevention and/or treatment of motoneuron diseases |
| 12/25/2003 | US20030236220 Mucin synthesis inhibitors |
| 12/25/2003 | US20030236218 Derivative of d4T having an electron withdrawing substituent on the aryl group and an amino acid substituent on the phosphate group |
| 12/25/2003 | US20030236217 Administering ADP-ribose |
| 12/25/2003 | US20030236216 For the treatment of diseases mediated by the Hepatitis C Virus |
| 12/25/2003 | US20030236213 Compounds useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders |
| 12/25/2003 | US20030236212 Compounds useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders |
| 12/25/2003 | US20030236209 Compositions and methods for the therapy and diagnosis of lung cancer |
| 12/25/2003 | US20030236203 Comprises praziquantel and/or pyrantel in solvent with thickener for improved bioavailability |
| 12/25/2003 | US20030236202 Natural products and derivatives thereof for protection against neurodegenerative diseases |
| 12/25/2003 | US20030236199 Mycrocycles useful in the teatment of Alzheimer's disease |
| 12/25/2003 | US20030236196 Polyoxyethylene glycol-modified tumor necrosis factor for higher concentrations, decreased viscosity, and improved stability; for treatment of inflammation |
| 12/25/2003 | US20030236193 Methods of treatment using specific binding agents of human angiopoietin-2 |
| 12/25/2003 | US20030236192 Method of modifying the release profile of sustained release compositions |
| 12/25/2003 | US20030236183 Comprises 5-HT4 receptor antagonists/agonists; for treatment of gastrointestinal disorders; veterinary medicine |
| 12/25/2003 | US20030236182 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders |
| 12/25/2003 | US20030235900 Anticancer agents |
| 12/25/2003 | US20030235891 Method for generating monoclonal antibodies |
| 12/25/2003 | US20030235867 Neuropeptide FF2 receptor, also known as GPR74, a G protein-coupled receptor (GPCR), and compositions and methods related thereto |
| 12/25/2003 | US20030235855 Assay for the detection of paclitaxel resistant cells in human tumors |
| 12/25/2003 | US20030235845 Directing splicing of messenger RNA associated with dystrophin protein for diagnosis and treatment of muscular dystrophy |
| 12/25/2003 | US20030235643 Food intermediate having sequestered phytosteryl esters in a polysaccharide matrix |
| 12/25/2003 | US20030235633 Preferential extraction of sterols and fatty acids using mixtures of ethanol and water; efficiency |
| 12/25/2003 | US20030235632 Heterocyclic ethers obtained from grapefruit juices, used as first pass effect antgonists; dietetics |
| 12/25/2003 | US20030235631 Administering mixtures of phosphodiesterase inhibitors, anxiolytic agents and antidepressants for prophylaxis of psycholical disorders; efficiency |
| 12/25/2003 | US20030235628 Mixtures of proton pump inhibitor such as lansoprazole and water soluble and insoluble bases, used for prophylaxis of gastrointestinal disorders; neutralization gastric juices |
| 12/25/2003 | US20030235626 Topical administration of pharmacologically active bases in the treatment of inflammatory dermatoses |
| 12/25/2003 | US20030235623 Antiseptic mixtures comprising hydrogen peroxide, peracetic acid, acetic acid, water and silver nitrate, used for purification of gases, surfaces, waste water treatment and pollution control |
| 12/25/2003 | US20030235619 Polymer-lipid delivery vehicles |
| 12/25/2003 | US20030235617 Pharmaceutical dosage form for mucosal delivery |
| 12/25/2003 | US20030235616 Pharmaceutical pills comprising drugs such as non-steroidal antiinflammatory agents, and cores surrounded by shells, having apertures for timed or sustained drug delivery |
| 12/25/2003 | US20030235615 Antibiotic composition with inhibitor |
| 12/25/2003 | US20030235614 Time release agents comprising drugs such as tacrolimus in solid solutions |
| 12/25/2003 | US20030235612 Compounds and compositions for delivering active agents |
| 12/25/2003 | US20030235611 Vesicle comprises ATP and phospholipid; fusion proteins |
| 12/25/2003 | US20030235610 Liposomes containing biologically active compounds |
| 12/25/2003 | US20030235609 Use of cholinesterase antagonists to treat insulin resistance |
| 12/25/2003 | US20030235607 Compositions and methods for inhibiting fungal growth and transference |
| 12/25/2003 | US20030235603 Comprises implantable/insertable implants (catheter, stents) |
| 12/25/2003 | US20030235596 Process for preparing a finely self-emulsifiable pharmaceutical composition |
| 12/25/2003 | US20030235592 Moraxella catarrhalis protein, gene sequence and uses thereof |
| 12/25/2003 | US20030235589 Comprises chondroprotective agents, an agent which promotes cartilage anabolic activity, and an agent that inhibits cartilage catabolism; for sustained release; for treatment of neurodegenerative disorders |
| 12/25/2003 | US20030235588 Thioredoxin (TRX); administering histone deacetylase inhibitors such as trichostatin A; for treating inflammation |
| 12/25/2003 | US20030235585 Methods of treating disorders in which TFN alpha activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor alpha |
| 12/25/2003 | US20030235583 Combined use of a modulator of CD3 and a beta cell resting compound |
| 12/25/2003 | US20030235576 Based on sodium channel blockers and fibrinolytics |
| 12/25/2003 | US20030235571 Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance |
| 12/25/2003 | US20030235552 Liquid fatty phase of a silicone oil structured with a graftpolyorganosiloxane gelling polymer having a molecular weight of 500-500000 that is solid at room temperature |
| 12/25/2003 | US20030235550 Antimicrobial compositions, products and methods employing same |
| 12/25/2003 | US20030235545 Cool and dry soft solid antiperspirant |
| 12/25/2003 | US20030235541 Topical administration of basic antifungal compositions to treat fungal infections of the nails |
| 12/25/2003 | US20030235537 Pulmonary delivery in treating disorders of the central nervous system |
| 12/25/2003 | US20030235536 Administering an aerosol, a conjugate of a therapeutic agent and an FcRn binding partner, for treating resipiratory system disorders, drug delivery of an antibody, immunizing vaccines |
| 12/24/2003 | WO2003107006A1 Oxaliplatin anti-resistance agent |
| 12/24/2003 | WO2003106970A2 P27 prevents cellular migration |
| 12/24/2003 | WO2003106660A2 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier |
| 12/24/2003 | WO2003106631A2 Methods and compositions relating to labeled rna molecules that reduce gene expression |
| 12/24/2003 | WO2003106630A2 Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference |
| 12/24/2003 | WO2003106629A2 Treating vitamin d responsive diseases |
| 12/24/2003 | WO2003106622A2 Methods for treatment of acute lymphocytic leukemia |
| 12/24/2003 | WO2003106507A1 Per (3,6-anhydro) cyclodextrin derivatives, their preparation and use thereof for separating ions, in particular chromium and manganese anions |
| 12/24/2003 | WO2003106506A1 Low molecular weight oversulfated polysaccharide |
| 12/24/2003 | WO2003106505A1 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained |
| 12/24/2003 | WO2003106504A1 Epimerized derivatives of k5 polysaccharide with a very high degree of sulfation |
| 12/24/2003 | WO2003106503A1 O-sulphated bacterial polysaccharides and their use |
| 12/24/2003 | WO2003106498A2 Agonistic binding molecules to the human ox40 receptor |
| 12/24/2003 | WO2003106474A2 Gangliosides with a modified acyl function |
| 12/24/2003 | WO2003106473A1 1-carboxymethyl analogues of glucosyl lipid a |
| 12/24/2003 | WO2003106472A1 Condensed palatinose and method for producing the same |
| 12/24/2003 | WO2003106469A1 Tumour-inhibiting platinum (ii) oxalate complexes |
| 12/24/2003 | WO2003106462A1 Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use |
| 12/24/2003 | WO2003106459A1 Amide substituted xanthine derivatives with gluconeogenesis modulating activity |
| 12/24/2003 | WO2003106456A2 New compounds |
| 12/24/2003 | WO2003106455A1 Azole methylidene cyanide derivatives and their use as protein kinase modulators |
| 12/24/2003 | WO2003106452A2 Antagonists of melanin concentrating hormone receptor |
| 12/24/2003 | WO2003106451A1 Substituted diaminopyrimidines |
| 12/24/2003 | WO2003106450A1 Phenylaminopyrimidines and their use as rho-kinase inhibitors |
| 12/24/2003 | WO2003106449A1 Novel aryl-{4-halo-4-[heteroarylmethylamino)-methyl]-piperidin-1-yl}-methanone derivatives, methods for production and use thereof as medicaments |
| 12/24/2003 | WO2003106446A1 Non-peptide gnrh agents, pharmaceutical compositions and methods for their use |
| 12/24/2003 | WO2003106445A1 Compounds and methods for controlling bacterial virulence |
| 12/24/2003 | WO2003106444A1 N,n-disubstituted diazocycloalkanes useful for the treatment of cns disorders due to serotonergic dysfunction |
| 12/24/2003 | WO2003106441A1 Pharmaceutical salts of reboxetine |
| 12/24/2003 | WO2003106439A1 Probe compound for image diagnosis of disease with amyloid accumulation, compound for staining age spots/diffuse age spots, and remedy for disease with amyloid accumulation |
| 12/24/2003 | WO2003106431A2 Novel hexahydro-pyridazine-3-carbocylic acid hydrazide or hydrazone derivatives, combinatorial libraries containing same, use thereof as medicines, pharmaceutical compositions containing same and methods for preparing same |
| 12/24/2003 | WO2003106428A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents |
| 12/24/2003 | WO2003106426A1 Compounds, compositions, and methods |
| 12/24/2003 | WO2003106425A2 Phenyl- and pyridyl-diazaheterocycles having a tnf-modulating activity |
| 12/24/2003 | WO2003106420A1 2,5-disubstituted 3-mercaptopentanoic acid |
| 12/24/2003 | WO2003106417A1 Mitotic kinesin inhibitors |
| 12/24/2003 | WO2003106416A2 Chemical process |
| 12/24/2003 | WO2003106413A2 Process for the preparation of oxazolidinones and method of use thereof |
| 12/24/2003 | WO2003106411A1 24-sulfoximine vitamin d3 compounds |
| 12/24/2003 | WO2003106410A1 Fluorinated cycloalkyl-derivatised benzoylguanidines and their use as a medicament |
| 12/24/2003 | WO2003106405A1 Aspartyl protease inhibitors |
| 12/24/2003 | WO2003106403A1 Carboxamides derivatives |
| 12/24/2003 | WO2003106402A1 2-naphtamide derivatives |
| 12/24/2003 | WO2003106401A1 N-bridged selective androgen receptor modulators and methods of use thereof |
| 12/24/2003 | WO2003106397A1 A process for preparing long chain saturated or unsaturated oxygenated compounds |